Immunome, Inc. (IMNM)
IMNM Stock Price Chart
Explore Immunome, Inc. interactive price chart. Choose custom timeframes to analyze IMNM price movements and trends.
IMNM Company Profile
Discover essential business fundamentals and corporate details for Immunome, Inc. (IMNM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Oct 2020
Employees
177.00
Website
https://www.immunome.comCEO
Clay Siegall
Description
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
IMNM Financial Timeline
Browse a chronological timeline of Immunome, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.51, while revenue estimate is $166.67k.
Earnings released on 12 May 2026
EPS came in at -$0.48 surpassing the estimated -$0.60 by +20.00%.
Earnings released on 3 Mar 2026
EPS came in at -$0.75 falling short of the estimated -$0.59 by -27.08%.
Earnings released on 6 Nov 2025
EPS came in at -$0.65 falling short of the estimated -$0.57 by -14.04%.
Earnings released on 6 Aug 2025
EPS came in at -$0.50 surpassing the estimated -$0.52 by +3.85%, while revenue for the quarter reached $4.02m , beating expectations by +381.80%.
Earnings released on 12 May 2025
EPS came in at -$0.52 surpassing the estimated -$0.66 by +21.21%, while revenue for the quarter reached $2.93m , beating expectations by +540.07%.
Earnings released on 19 Mar 2025
EPS came in at -$0.84 falling short of the estimated -$0.68 by -23.53%, while revenue for the quarter reached $2.74m , missing expectations by -12.99%.
Earnings released on 13 Nov 2024
EPS came in at -$0.78 falling short of the estimated -$0.60 by -30.00%, while revenue for the quarter reached $2.91m , missing expectations by -7.79%.
Earnings released on 12 Aug 2024
EPS came in at -$0.49 falling short of the estimated -$0.38 by -28.95%, while revenue for the quarter reached $2.36m , missing expectations by -7.29%.
Earnings released on 14 May 2024
EPS came in at -$0.34 surpassing the estimated -$0.80 by +57.50%, while revenue for the quarter reached $1.03m , missing expectations by -63.25%.
Earnings released on 28 Mar 2024
EPS came in at -$0.54 falling short of the estimated -$0.28 by -92.86%, while revenue for the quarter reached $3.83m , beating expectations by +85.13%.
Earnings released on 9 Nov 2023
EPS came in at -$0.36 falling short of the estimated -$0.17 by -111.76%, while revenue for the quarter reached $3.57m , meeting expectations.
Earnings released on 9 Aug 2023
EPS came in at -$0.46 falling short of the estimated -$0.16 by -187.50%, while revenue for the quarter reached $4.26m .
Earnings released on 5 May 2023
EPS came in at -$0.35 falling short of the estimated $0.59 by -159.32%, while revenue for the quarter reached $2.36m .
Earnings released on 16 Mar 2023
EPS came in at -$0.64 falling short of the estimated $0.67 by -195.52%.
Earnings released on 14 Nov 2022
EPS came in at -$0.75 surpassing the estimated -$0.76 by +1.32%.
Earnings released on 5 Aug 2022
EPS came in at -$0.74 surpassing the estimated -$0.75 by +1.33%.
Earnings released on 12 May 2022
EPS came in at -$0.96 falling short of the estimated -$0.69 by -39.13%.
Earnings released on 28 Mar 2022
EPS came in at -$0.66 surpassing the estimated -$0.81 by +18.52%.
Earnings released on 15 Nov 2021
EPS came in at -$0.65 falling short of the estimated -$0.50 by -30.00%.
Earnings released on 16 Aug 2021
EPS came in at -$0.46 falling short of the estimated -$0.39 by -17.95%.
IMNM Stock Performance
Access detailed IMNM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
